Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Eric Schweitzer | M | 59 |
Freie Universität Berlin
| 6 years |
Wolfgang Oster | M | - |
AplaGen GmbH
AplaGen GmbH BiotechnologyHealth Technology AplaGen was founded in April 2001 by Prof. Dr. med. Hans-Georg Frank, Prof. Dr. med. Peter Kaufmann and Dr. Franzpeter Bracht. Its basic technologies were a spin-off of the University of Technology Aachen, Germany (RWTH). From this starting point, AplaGen has transformed into a company with broad expertise in peptide design, synthesis and analysis. It has successfully developed own products with independent patent protection for major markets, including the anemia market (EPO-market) and the thrombocytopenia market. The discovery of cytokine-mimetic peptides defines its core expertise. With its proprietary cytokine-mimetic peptide products, AplaGen is approaching large existing biopharmaceutical markets in a 'smart-follower' position, which provides an optimal risk/chance profile. Pharmacokinetic optimization of peptides is based on the approved drug Hydroxyethylstarch (HES) and protected by AplaGen´s IP. As privately held company, AplaGen has closed seed financing in 2001 and a series financing in 2005. AplaGen is dedicated to improvements for patients with dysfunctional bone marrow, especially oncologic patients. Both, erythropoietin and Thrombopoietin mimetic peptides will be developed by AplaGen at least until Phase II. To support this focus on oncologic indications AplaGen is seeking early partners for the erythropoietin mimetic peptide in the indication of renal anemia. | - |
Pamela Knapp | F | 66 |
Freie Universität Berlin
| 4 years |
Olaf Kunz | M | 64 |
Freie Universität Berlin
| 3 years |
Hanns-Alexander Klemm | M | - |
Freie Universität Berlin
| 3 years |
Christine Wolff | F | 63 |
Freie Universität Berlin
| 1 years |
Frank Czichowski | M | 64 |
Freie Universität Berlin
| 6 years |
Marion Dorsch | M | 59 |
Freie Universität Berlin
| 7 years |
Martin Auer | M | 64 |
Freie Universität Berlin
| 3 years |
Stefan Herm | M | - |
Freie Universität Berlin
| 5 years |
Niko Stumpfögger | M | 68 |
Freie Universität Berlin
| 2 years |
S. Gottfried von Hase | M | - |
Freie Universität Berlin
| 4 years |
Frank Conarad | M | 62 |
Freie Universität Berlin
| 4 years |
Andreas Tietmann | M | 61 |
AplaGen GmbH
AplaGen GmbH BiotechnologyHealth Technology AplaGen was founded in April 2001 by Prof. Dr. med. Hans-Georg Frank, Prof. Dr. med. Peter Kaufmann and Dr. Franzpeter Bracht. Its basic technologies were a spin-off of the University of Technology Aachen, Germany (RWTH). From this starting point, AplaGen has transformed into a company with broad expertise in peptide design, synthesis and analysis. It has successfully developed own products with independent patent protection for major markets, including the anemia market (EPO-market) and the thrombocytopenia market. The discovery of cytokine-mimetic peptides defines its core expertise. With its proprietary cytokine-mimetic peptide products, AplaGen is approaching large existing biopharmaceutical markets in a 'smart-follower' position, which provides an optimal risk/chance profile. Pharmacokinetic optimization of peptides is based on the approved drug Hydroxyethylstarch (HES) and protected by AplaGen´s IP. As privately held company, AplaGen has closed seed financing in 2001 and a series financing in 2005. AplaGen is dedicated to improvements for patients with dysfunctional bone marrow, especially oncologic patients. Both, erythropoietin and Thrombopoietin mimetic peptides will be developed by AplaGen at least until Phase II. To support this focus on oncologic indications AplaGen is seeking early partners for the erythropoietin mimetic peptide in the indication of renal anemia. | - |
Marion Helmes | M | 58 |
Freie Universität Berlin
| 4 years |
René Wolfgang Franz Gawron | M | 63 |
Freie Universität Berlin
| 2 years |
Henrik Colell | M | 61 |
Freie Universität Berlin
| 4 years |
Bernd Buchholz | M | 62 |
Freie Universität Berlin
| 4 years |
Shawn Hecht | M | - |
Freie Universität Berlin
| 1 years |
Petra Wierzchowski | F | 58 |
Freie Universität Berlin
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
Germany | 20 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hans-Georg Frank
- Personal Network